Too Much SAMA, Too Many Exacerbations: A Call for Caution in Asthma

Area of Science:

• Pulmonology
• Real-world evidence
• Pharmacovigilance

Background:

• Over-reliance on short-acting beta2-agonists (SABAs) is linked to poor asthma outcomes.
• The impact of frequent short-acting muscarinic antagonist (SAMA) use on asthma exacerbations is not well-defined.
• Current asthma guidelines lack recommendations for SAMA overuse.

Purpose of the Study:

• To conduct the first real-world analysis of SAMA overuse in asthma.
• To quantify the association between SAMA use and asthma exacerbation risk.
• To compare the predictive value of SAMA use versus SABA use for asthma outcomes.

Main Methods:

• Retrospective multicenter cohort study of 132 adult asthma patients in the Spanish National Health System.
• Analysis of electronic health records (EHRs) using negative binomial regression and bootstrap simulations.
• Application of interaction and threshold models to identify SAMA use cutoffs and their impact on outcomes.

Main Results:

• SAMA use was independently linked to a 19.2% increase in exacerbation frequency per canister.
• Frequent SAMA use (≥2.5 canisters/year) was associated with a nearly sixfold increased odds of experiencing ≥1 exacerbation.
• Increased SAMA use correlated with higher healthcare utilization, including respiratory consultations and prescriptions for systemic corticosteroids and antibiotics.

Conclusions:

• SAMA overuse is a significant, digitally traceable indicator of asthma instability.
• Findings suggest SAMA tracking could complement SABA monitoring in asthma management tools.
• Early identification of uncontrolled asthma via SAMA use can guide timely therapeutic adjustments.